LY-3526318

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameLY-3526318
Drug Alias NameLY-3526318HX-260
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransient receptor potential cation channel subfamily A member 1 inhibitors
TargetsTransient receptor potential cation channel subfamily A member 1
Therapy Area/IndicationsLow Back PainDiabetic NeuropathiesOsteoarthritis, Knee
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPuerto Rico +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsLow Back PainDiabetic NeuropathiesOsteoarthritis, Knee
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A